Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

doi:10.1182/blood.2024027948

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Blood - 5 Feb 2026

Turkalj Sven, Radtke Felix A, Stoilova Bilyana, Mecklenbrauck Rabea, Groom Angus J, Jakobsen Niels Asger, Lachowiez Curtis A, Metzner Marlen, Usukhbayar Batchimeg, Salazar Mirian Angulo, Zeng Zhihong, Loghavi Sanam, Marvin-Peek Jennifer, Körber Verena, Ravandi Farhad, Issa Ghayas, Kadia Tapan, Symeonidou Vasiliki, de Groot Anne P, Kantarjian Hagop, Takahashi Koichi, Konopleva Marina, DiNardo Courtney D, Vyas Paresh

Abstract excerpt

ABSTRACT: Acquired resistance to targeted, nonintensive therapies is common in myeloid malignancies. However, the kinetics of selection, the hematopoietic cell compartments in which selection occurs, and the molecular mechanisms underlying selection remain open questions. To address this, we studied the kinetics of clonal and transcriptional responses to combinational therapy with ivosidenib plus venetoclax, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Clonal Evolution

Share to Glycine

Share to Hematopoietic Stem Cells

Share to Isocitrate Dehydrogenase

Share to Pyridines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 41191518
DOI: 10.1182/blood.2024027948
PMCID: PMC13000948

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.PMID 41191518Read ↗

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapySemantic proximity Read ↗

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.Semantic proximity Read ↗

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSemantic proximity Read ↗

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistanceSemantic proximity Read ↗

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Therapy-Induced Clonal Selection as a Driver of Response to JAK Inhibitors in MyelofibrosisSemantic proximity Read ↗

Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.Semantic proximity Read ↗

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.Semantic proximity Read ↗

Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic ProgramsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.